Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2020

01-01-2020 | Gastric Cancer | Editorial

Early Gastric Cancer with Mixed-Type Histology: A Mixed Bag or Pure Evil?

Author: Mohamed O. Othman

Published in: Digestive Diseases and Sciences | Issue 1/2020

Login to get access

Excerpt

Undifferentiated or poorly differentiated gastric adenocarcinoma carries a higher risk of lymph node metastasis (LNM) than do more well-differentiated tumors, which was shown to be as high as 9% in a published trial [1]. In a meta-analysis of 23 studies focusing on LNM in undifferentiated gastric adenocarcinoma, the following risk factors were identified as predictors for LNM: female sex, age > 60 years, a tumor > 2 cm, ulcerated lesions, submucosal invasion, lymphovascular invasion, non-signet ring carcinoma, or tumor located outside the gastric corpus [2]. Although the risk of LNM for undifferentiated early gastric adenocarcinoma (EGC) is well studied, tumors with mixed differentiation types are not well studied. The Japanese classification of gastric carcinoma does not recognize mixed differentiation as a separate entity. A tumor with mixed differentiation where the majority of the tumor is well-differentiated is considered as a differentiated tumor despite the presence of a small, undifferentiated component. The same holds true for a predominantly undifferentiated tumor with a small differentiated component that is treated as an undifferentiated tumor [3]. Whether a tumor with mixed differentiation is truly a different entity and whether it carries the same risk of LNM as seen in an undifferentiated tumor is a matter of debate. In this issue of Digestive Disease and Sciences, Bang et al. [4] tackled the difficult task of assessing the risk of LNM and outcomes of endoscopic submucosal dissection (ESD) in patients with EGC of mixed-type histology (MH). The systematic review included eight retrospective studies that reported the outcomes of ESD in the management of EGC in 458 patients with MH. The authors found that EGC with MH (EGC-MH) has higher rates of submucosal invasion compared with purely differentiated or even purely undifferentiated EGC. One of the included trials showed a higher rate of lymphovascular invasion in EGC with MH compared to EGC with purely undifferentiated histology [5]. Pooled meta-analysis showed an en-bloc resection rate of 94.6% with a curative resection rate of only 55.1% (95% CI 50.4–59.6%) for EGC-MH; significantly less than reported for other types of EGC. Finally, one of the included studies in this systematic review showed a higher recurrence rate after ESD in EGC-MH compared with purely undifferentiated gastric cancer [6]. I congratulate the authors on their extensive research and analysis of the literature. Data regarding EGC-MH are extremely rare; the authors had to ‘read between the lines’ to extract such valuable information. The take-home point from this study is that EGC-MH should be treated with extreme caution given its high rate of non-curative resection in addition to a higher recurrence rate after endoscopic resection. The presence of a differentiated component within these tumors did not offer any advantage compared to the purely undifferentiated gastric cancer. As was alluded to some of the included studies, EGC with mixed histology can behave even more aggressively than do undifferentiated tumors. Recent data suggest that there is a subset of patients with undifferentiated EGC who are at low risk of LNM. In a retrospective study of 1425 patients with undifferentiated gastric cancer treated surgically, no LNM was detected in patients with an intramucosal tumor < 4 cm with no ulceration or evidence of lymphovascular invasion in the resected specimen (95% CI 0–6%) [7]. …
Literature
1.
go back to reference Fang WL, Huang KH, Lan YT, et al. The risk factors of lymph node metastasis in early gastric cancer. Pathol Oncol Res. 2015;21:941–946.CrossRef Fang WL, Huang KH, Lan YT, et al. The risk factors of lymph node metastasis in early gastric cancer. Pathol Oncol Res. 2015;21:941–946.CrossRef
2.
go back to reference Zhao X, Cai A, Xi H, et al. Predictive factors for lymph node metastasis in undifferentiated early gastric cancer: a systematic review and meta-analysis. J Gastrointest Surg. 2017;21:700–711.CrossRef Zhao X, Cai A, Xi H, et al. Predictive factors for lymph node metastasis in undifferentiated early gastric cancer: a systematic review and meta-analysis. J Gastrointest Surg. 2017;21:700–711.CrossRef
3.
go back to reference Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.CrossRef Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.CrossRef
5.
go back to reference Lee JH, Kim JH, Rhee K, et al. Undifferentiated early gastric cancer diagnosed as differentiated histology based on forceps biopsy. Pathol Res Pract. 2013;209:314–318.CrossRef Lee JH, Kim JH, Rhee K, et al. Undifferentiated early gastric cancer diagnosed as differentiated histology based on forceps biopsy. Pathol Res Pract. 2013;209:314–318.CrossRef
6.
go back to reference Han JP, Hong SJ, Kim HK. Long-term outcomes of early gastric cancer diagnosed as mixed adenocarcinoma after endoscopic submucosal dissection. J Gastroenterol Hepatol. 2015;30:316–320.CrossRef Han JP, Hong SJ, Kim HK. Long-term outcomes of early gastric cancer diagnosed as mixed adenocarcinoma after endoscopic submucosal dissection. J Gastroenterol Hepatol. 2015;30:316–320.CrossRef
9.
go back to reference Pyo JH, Lee H, Min BH, et al. Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. J Gastroenterol. 2017;52:594–601.CrossRef Pyo JH, Lee H, Min BH, et al. Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. J Gastroenterol. 2017;52:594–601.CrossRef
Metadata
Title
Early Gastric Cancer with Mixed-Type Histology: A Mixed Bag or Pure Evil?
Author
Mohamed O. Othman
Publication date
01-01-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05919-6

Other articles of this Issue 1/2020

Digestive Diseases and Sciences 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.